Episodes

  • Top Takeaways from 2025: Preventive Cardiology with C. Noel Bairey Merz, MD, MACC

    Top Takeaways from 2025: Preventive Cardiology with C. Noel Bairey Merz, MD, MACC
    Dec 18 2025
    In this interview, C. Noel Bairey Merz MD, MACC and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2025 including trials clopidogrel versus aspirin, the benefit of vaccines, statin use in pregnancy, and more. Suggested Materials: Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4 O'Leary K. Influenza vaccination benefits patients with heart failure. Nature Medicine. 2025. doi: https://doi.org/10.1038/d41591-025-00058-0 Christensen JJ, Holven KB, Bogsrud MP, et al. Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study. Eur Heart J. Published online August 21, 2025. doi:10.1093/eurheartj/ehaf592 Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi:10.1002/oby.24336 Brett AS. New Variations on GLP-1–Receptor Agonists are Coming (NEJM/Clinician website). 2025. Available at: https://clinician.nejm.org/new-variations-glp-1receptor-agonists-coming-nejm-jw.NA58926. Accessed 12/17/25. Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    15 mins
  • Top Takeaways from 2025: EP with DJ Lakkireddy, MBBS, FACC

    Top Takeaways from 2025: EP with DJ Lakkireddy, MBBS, FACC
    Dec 17 2025
    In this interview, DJ Lakkireddy, MBBS, FACC and Alison L. Bailey, MD FACC, discuss the Top Electrophysiology Takeaways from 2025 including trials CLOSURE-AF, ALONE-AF, NEMESIS-PFA, and more. Suggested Materials: 1. Verma A, Birnie DH, Jiang C, et al. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. Published online November 8, 2025. doi:10.1056/NEJMoa2509688 2. Landmesser U, Skurk C, Kirchhof P, et al. Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial. Am Heart J. Published online September 12, 2025. doi:10.1016/j.ahj.2025.09.005 3. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679 4. Lakkireddy D, Katapadi A, Garg J, et al. NEMESIS-PFA: Investigating Collateral Tissue Injury Associated With Pulsed Field Ablation. JACC Clin Electrophysiol. 2025;11(8):1747-1756. doi:10.1016/j.jacep.2025.04.017 5. Wazni OM, Saliba WI, Nair DG, et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. 2025;392(13):1277-1287. doi:10.1056/NEJMoa2408308 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    19 mins
  • Multimodality Imaging in Inflammatory Cardiomyopathy

    Multimodality Imaging in Inflammatory Cardiomyopathy
    Dec 16 2025

    Multimodality imaging plays a pivotal role in evaluating inflammatory cardiomyopathy, particularly when cardiac sarcoidosis (CS) is suspected. Symptoms of CS include unexplained high-grade AV block, ventricular arrhythmias, reduced left ventricular function, or regional wall thinning without coronary disease. The best evaluation combines cardiac magnetic resonance imaging (MRI) for structural and scar assessment with fluorodeoxyglucose (FDG)-positron emission tomography (PET) for detecting active inflammation and extracardiac involvement.

    In this interview, Michelle Kittleson MD, FACC and Ron Blankstein, MD, FACC discuss "Multimodality Imaging in Inflammatory Cardiomyopathy."

    Subscribe on Apple Podcasts | Subscribe to ACCEL

    Show More Show Less
    9 mins
  • Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC

    Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC
    Dec 11 2025
    In this interview, Allen J. Taylor, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Clinical Cardiology Takeaways from 2025 including trials SCOT-HEART 2, ALONE-AF, Launch-HTN, and more. Suggested Materials: 1. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679 2. Lemesle G, Didier R, Steg PG, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025;393(16):1578-1588. doi:10.1056/NEJMoa2507532 3. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 4. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 5. Saxena M, Laffin L, Borghi C, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025;334(5):409-418. doi:10.1001/jama.2025.9413 6. McDermott M, Khaing PH, Meah MN, et al. CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial. JAMA Cardiol. 2025;10(8):841-850. doi:10.1001/jamacardio.2025.1763 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    19 mins
  • Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC

    Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC
    Dec 10 2025
    In this interview, Deepak Bhatt, MD, MPH, FACC and Alison L. Bailey, MD FACC, discuss the Top Interventional Cardiology Takeaways from 2025 including DanGer Shock trial, revascularization in STEMI, aspirin withdrawal after PCI, and more. Suggested Materials: 1. Møller JE, Beske RP, Engstrøm T, et al. Long-Term Outcomes of the DanGer Shock Trial. N Engl J Med. 2025;393(10):1037-1038. doi:10.1056/NEJMc2508284 2. Ueyama HA, Akita K, Kiyohara Y, et al. Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis. J Am Coll Cardiol. 2025;85(1):19-38. doi:10.1016/j.jacc.2024.09.1231 3. Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med. 2025;392(3):217-227. doi:10.1056/NEJMoa2405880 4. Guimarães PO, Franken M, Tavares CAM, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. Published online August 31, 2025. doi:10.1056/NEJMoa2507980 5. Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    17 mins
  • PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD

    PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD
    Dec 9 2025
    he PANTHER study indicates that clopidogrel provides superior protection against major cardiovascular events compared to aspirin in patients with coronary artery disease, without increasing bleeding risk. This supports its use in individuals at higher risk of gastrointestinal complications, reinforcing current clinical preferences. Overall, these results could inform long-term treatment strategies and improve outcomes for millions of patients worldwide. In this interview, Alison L. Bailey, MD, FACC and Prof. Marco Valgimigli discuss "PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD". Suggested Materials: 1. Giacoppo D, Gragnano F, Watanabe H, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ. 2025;389:e082561. Published 2025 Jun 4. doi:10.1136/bmj-2024-082561 2. Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024;404(10456):937-948. doi:10.1016/S0140-6736(24)01616-7 3. P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration. J Am Coll Cardiol. 2023;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    12 mins
  • ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC

    ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC
    Dec 4 2025
    In this interview, Clyde Yancy MD, MSc, MACC and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2025 including trials SUMMIT and BaxHTN, the ACC/AHA Blood Pressure Guidelines, and more. Suggested Materials: 1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567-1678. doi:10.1016/j.jacc.2025.05.007 2. Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(24):1982-2004. doi:10.1161/CIR.0000000000001191 3. Yancy CW. Heart Failure: A Century View, From Failure to Function. Circulation. 2025;151(9):585-588. doi:10.1161/CIRCULATIONAHA.124.072249 4. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 5. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    20 mins
  • ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC

    ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC
    Dec 3 2025
    In this interview, Amit R. Patel, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Cardiovascular Imaging Takeaways from 2025 including myocardial fibroblast activation, photon-counting detector CT, the newly published ACC/AHA CT Advanced Training Statement, and more. Suggested Materials: 1. Nijveldt R, Maeng M, Beijnink CWH, et al. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. N Engl J Med. Published online October 28, 2025. doi:10.1056/NEJMoa2512918 2. Barton AK, Craig NJ, Loganath K, et al. Myocardial Fibroblast Activation After Acute Myocardial Infarction: A Positron Emission Tomography and Magnetic Resonance Study. J Am Coll Cardiol. 2025;85(6):578-591. doi:10.1016/j.jacc.2024.10.103 3. Sakai K, Shin D, Singh M, et al. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025;85(4):339-348. doi:10.1016/j.jacc.2024.10.069 4. Baldassarre LA, Mendes LA, Blankstein R, et al. 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency Management Committee. J Am Coll Cardiol. Published online November 18, 2025. doi:10.1016/j.jacc.2025.07.036 5. Sahashi Y, Ieki H, Yuan V, et al. Artificial Intelligence Automation of Echocardiographic Measurements. J Am Coll Cardiol. 2025;86(13):964-978. doi:10.1016/j.jacc.2025.07.053 Subscribe on Apple Podcasts | Subscribe to ACCEL
    Show More Show Less
    15 mins